COLL vs GS · P/E 17, rev $181.9M vs P/E 20, $324.25B cap
Collegium Pharmaceutical Inc (COLL) versus Goldman Sachs Group Inc (GS) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
GS does not have a complete income-statement cache yet.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Not investment advice. Open the COLL and GS stock pages for the full models.
Not investment advice.